<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02027116</url>
  </required_header>
  <id_info>
    <org_study_id>VGX-6150-01</org_study_id>
    <nct_id>NCT02027116</nct_id>
  </id_info>
  <brief_title>Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection</brief_title>
  <acronym>VGX-6150-01</acronym>
  <official_title>Multi-center, Open-label, Dose Escalation, Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneOne Life Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inovio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneOne Life Science, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability and immunogenicity of VGX-6150 as second-line therapy in
      chronic hepatitis C patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Screening ~ week 36</time_frame>
    <description>To evaluate the safety and tolerability of VGX-6150 as second-line therapy in chronic hepatitis C patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity and virologic response</measure>
    <time_frame>Screening ~ Week 36</time_frame>
    <description>To evaluate the immunogenicity and virologic response to VGX-6150 in treatment failure patients with chronic hepatitis C</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Experimental: 1mg of DNA/dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a 3 dose series of VGX-6150 containing 1mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: 3mg of DNA/dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a 3 dose series of VGX-6150 containing 3mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: 6mg of DNA/dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a 3 dose series of VGX-6150 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VGX-6150</intervention_name>
    <description>Plasmid DNA delivered via IM injection with electroporation</description>
    <arm_group_label>Experimental: 1mg of DNA/dose</arm_group_label>
    <arm_group_label>Experimental: 3mg of DNA/dose</arm_group_label>
    <arm_group_label>Experimental: 6mg of DNA/dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who want to participate in this trial should meet all of the following
             criteria.

               1. Male or females aged 19 to 65 years

               2. Chronic hepatitis C patients infected with HCV genotype 1a or 1b

               3. Patients who failed* SOC therapy with PEG-IFN and ribavirin or triple therapy
                  with SOC and DAA agents

                  *Treatment failure is defined by any of the following; A. Partial response (PR)
                  Serum HCV RNA level declined by at least 2 log10 but still detected at treatment
                  week 24 B. Non-response (NR) Serum HCV RNA level not declined by at least 2 log10
                  at treatment week 12 C. Relapse Serum HCV RNA undetected during treatment but
                  detectable after end of treatment D. Treatment discontinuation due to ADR or
                  other reason

               4. Patients whose deltoid muscles (left or right) are accessible by 12 to 19 mm
                  cannula/ electrode for intramuscular (IM) injection and electroporation (EP)

               5. Patients who can comply with planned schedule of this protocol

               6. Patients who give written informed consent voluntarily

        Exclusion Criteria:

          -  Subjects who meet any of the followings cannot participate in this study.

               1. Liver transplant recipients

               2. Patients having decompensated liver cirrhosis with any history or evidence of
                  ascites, esophageal variceal hemorrhage and/or hepatic encephalopathy

               3. Malignant tumor patients who received radiotherapy or chemotherapy before study
                  participation

               4. Current active infection except hepatitis C that requires medical treatment

               5. Autoimmune disease patients or immunodeficient (immuno-compromised) patients

               6. Patients who received immunomodulators, cytotoxic agents or systemic
                  corticosteroids for chronic disease other than hepatitis C within 2 months before
                  study participation

               7. Patients who received non-steroidal anti-inflammatory drugs (NSAIDs) within 10
                  days before IP administration

               8. Concomitant diseases which is judged to be unacceptable for study participation
                  by investigator (e.g., severe cardiovascular, renal , or psychiatric disease)

               9. Clinically significant abnormal findings in physical examination,laboratory
                  tests, vital signs or ECG at investigator's discretion

              10. Patients with implantable pacemaker

              11. Patients with metal implant in IP administration area or nearby

              12. Positive for HBsAg, or HIV Ab

              13. Previous history of gene therapy

              14. History of allergy or anaphylaxis to any component of IP or other vaccine

              15. Patients who received major surgery within 4 weeks before IP administration

              16. Blood transfusion within 4 weeks before IP administration

              17. Current alcohol or drug abuse

              18. Patients who received other vaccine within 30 days before IP administration

              19. Pregnancy or breast-feeding woman

              20. Women of childbearing potential (WOCBP) or men with partner of WOCBP who are
                  unwilling to use adequate contraception or be abstinent during the trial

              21. Patients who received other investigational products within 30 days before study
                  participation

              22. Patients incapable of participating in this trial by investigator's judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Hoon Ahn, M.D, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeong Heo, M.D, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2014</study_first_submitted>
  <study_first_submitted_qc>January 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2014</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic hepatitis C</keyword>
  <keyword>DNA Vaccine</keyword>
  <keyword>Electroporation</keyword>
  <keyword>Intramuscular (IM) Injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

